Nightingale Health completes the analysis of all 500,000 UK Biobank samples creating the world's largest blood biomarker database for chronic disease research and prevention
Press release, 13 December 2023 at 8:30 a.m. (EET)
Nightingale Health Plc ("Nightingale Health"), a technology company promoting preventative health with its proprietary health risk detection platform, announced today that it has completed the analysis of blood samples from all 500,000 UK Biobank participants. UK Biobank is the world's most comprehensive source of health data used for research, renowned for its vast and continuously growing dataset of biological, health and lifestyle information.The de-identified data is globally accessible to approved researchers who are undertaking health-related research that is in the public interest. The analysis results will be made available to UK Biobank's over 30,000 registered researchers from over 90 countries.
Nightingale Health stands out as the sole broad biomarker profiling provider to analyze all 500,000 samples in the UK Biobank. This unique position comes from Nightingale Health's technology's ability to analyze vast numbers of samples at a quality and cost level that no other technology can match. With Nightingale Health's biomarkers integrated into UK Biobank's database, the company has become the leading source of blood biomarker data for scientific research. More crucially, the wide scientific use of Nightingale Health's biomarkers has already enabled the company's technology to be routinely adopted in clinical settings, marking a leap forward in chronic disease treatment and prevention.
"This is a historic milestone not only for Nightingale Health but also for the global scientific community. Never before has this kind of comprehensive metabolic data been available to enhance the understanding of chronic diseases that cause the largest burden to healthcare systems worldwide. The scientific results speak for themselves already as the published findings demonstrate the unprecedented value and opportunities that Nightingale Health's data brings to scientific research," says Jeffrey Barrett, Nightingale Health's Chief Scientific Officer.
"No other company in the world has managed to reach a similar level of scientific scrutiny and medical evidence as Nightingale Health in understanding chronic diseases, which has already enabled the adoption of our technology in national scale clinical use cases in next-generation health screening. We are extremely proud of what we have achieved over the past 10 years, but I believe this is just a start – with this pace of scientific and technological progress, we will soon be replacing many of the aging solutions in primary healthcare with better tools for chronic disease detection to make our health systems more preventative, effective and smarter. This is an exciting and better future for everyone, and we are implementing it already around the world," says Teemu Suna, Nightingale Health's CEO and Founder.
Nightingale Health's technology, a global standard in population studies and large biobanks, has been used to analyze over 2.1 million blood samples to date. This broad use is reflected in more than 530 peer-reviewed publications by scientists from 170 institutions in 34 countries. The results analyzed from each blood sample include 250 biomarkers, of which 39 are clinically validated and can be used in the same way as traditional clinical biomarkers.
In addition to research, Nightingale Health's technology is entering wide-scale clinical use. In Finland, the country's largest private healthcare provider, Terveystalo, has replaced aging clinical chemistry tools with Nightingale Health's biomarkers and risk prediction models in routinely performed health checks which cover approximately 30% of the Finnish working population. In addition to Finland, the clinical use of the technology is expanding to healthcare providers in Singapore via Innoquest Diagnostics and to other Southeast Asian countries through Pathology Asia group companies. The access to Nightingale Health's biomarker data via UK Biobank paves the way for further national implementations worldwide as the advancements of the technology can be transparently validated, helping healthcare systems enter the era of preventative health.
For further information, please contact:
Teemu Suna, CEO
ir@nightingalehealth.com
About Nightingale Health
Nightingale Health is The Preventative Health Company. Staying healthy is one of the top priorities in human life. Our health has a profound impact on our quality of life, and it’s also strongly connected to the lives of those close to us. Nightingale Health enables prevention by combining the power of our in-house developed, advanced blood analysis technology with unprecedented access to global health repositories and world-leading medical research. With this combination, we go beyond the traditional healthcare and wellbeing tools: We provide the scientific connection to multiple health and disease outcomes and the ability to predict future healthy years.
Nightingale Health operates globally with a parent company in Finland and seven subsidiaries in countries such as Japan, the United States, Singapore, and the United Kingdom. Nightingale Health has customers in more than 25 countries in the healthcare and medical research sectors. The company’s technology is being used in many of the world’s leading health initiatives, such as the UK Biobank, and over 450 peer-reviewed publications validate the technology. The company’s Series B shares are listed on the First North Growth Market Finland marketplace. Read more: https://nightingalehealth.com
About UK Biobank
UK Biobank is a large-scale biomedical database and research resource containing de-identified genetic, lifestyle and health information and biological samples from half a million UK participants. It is the most comprehensive and widely-used dataset of its kind, and is globally accessible to approved researchers who are undertaking health-related research that is in the public interest, whether they are from academic, commercial, government or charitable settings. UK Biobank is helping to advance modern medicine and enable better understanding of the prevention, diagnosis, and treatment of a wide range of serious and life-threatening illnesses – including cancer, heart disease and stroke. Over 30,000 researchers from more than 90 countries are registered to use UK Biobank and more than 9,000 peer-reviewed papers have been published as a result. UK Biobank is supported by Wellcome and the Medical Research Council, as well as the British Heart Foundation, Cancer Research UK, the UK Government’s National Institute for Health and Care Research and Department of Science, Innovation and Technology, Griffin Catalyst and Schmidt Futures.
www.ukbiobank.ac.uk, @uk_biobank, Facebook, LinkedIn, Instagram
Tags:
